Skip to main content
SpringerLink
Log in

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

  • Invited Commentary
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2.

    PubMed  Google Scholar 

  2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  PubMed  Google Scholar 

  4. Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.

    Article  CAS  PubMed  Google Scholar 

  5. Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. ASH Annual Meeting Abstracts. 2012;120:3554.

    Google Scholar 

  6. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188–202.

    Article  CAS  PubMed  Google Scholar 

  7. Brunetti L, Di Battista V, Venanzi A, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31:1238–40.

    Article  CAS  PubMed  Google Scholar 

  8. Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.

    Article  CAS  PubMed  Google Scholar 

  9. Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.

    Article  CAS  PubMed  Google Scholar 

  10. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–84.

    Article  CAS  PubMed  Google Scholar 

  11. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker research. 2014;2:4.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Frankel A. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. ASCO Annual Meeting 2013. J Clin Oncol (Meeting Abstracts). 2013;31(15_suppl):7029.

    Google Scholar 

  13. Pemmaraju N et al. Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood (ASH abstract #4245, Dec 2016) 2016.

  14. Pemmaraju NLA, Sweet KL, Stein A, Sumithira V, Blum WG. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): lead-in completed, expansion stage ongoing. J Clin Oncol 2016; 34 (suppl; abstr 7006).

  15. Cai T, Galetto R, Gouble A, et al. Pre-clinical studies of anti-CD123 CAR-T cells for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2016;128:4039.

    Article  Google Scholar 

  16. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Nievergall E, Ramshaw HS, Yong AS, et al. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123:1218–28.

    Article  CAS  PubMed  Google Scholar 

  18. Bonifant CL, Szoor A, Torres D, et al. CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia. Mol Ther. 2016;24:1615–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129:2395–407.

    Article  CAS  PubMed  Google Scholar 

  20. Seung Y, Chu EP, Chen H, Phung S, Chan EW, Endo NA, et al. Immunotherapy with long-lived anti-CD123 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood (ASH abstract). 2014;124:2316.

    Article  Google Scholar 

  21. Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sapienza MR, Fabio F, Claudio A, et al. Molecular profiling of blastic plasmacytoid dendritic CELL neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Blood. 2013;122:2502.

    Google Scholar 

  23. Philippe L, Ceroi A, Bole-Richard E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017; https://doi.org/10.3324/haematol.2017.169326.

  24. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.

    Article  CAS  PubMed  Google Scholar 

  25. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.

  26. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer discovery. 2016;6:1106–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discovery. 2017;7:156–64.

    Article  CAS  PubMed  Google Scholar 

  28. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Emadali A, Hoghoughi N, Duley S, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016;127:3040–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research is supported in part by the MD Anderson Cancer Center Support Grant P30 CA016672.

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Unit 428, PO BOX 301402, Houston, TX, 77230-1402, USA

    Naveen Pemmaraju

Authors
  1. Naveen Pemmaraju
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naveen Pemmaraju.

Ethics declarations

Conflict of Interest

Naveen Pemmaraju reports Honorarium/Consulting and/or Research/Grant & Clinical trial support: Novartis, LFB, Incyte, Stemline, Cellectis, Abbive, Affymetrix, Roche Diagnostics. Dr. Pemmaraju is a section editor for Current Hematologic Malignancy Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pemmaraju, N. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. Curr Hematol Malig Rep 12, 510–512 (2017). https://doi.org/10.1007/s11899-017-0425-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-017-0425-7

Keywords

Search

Navigation